Medicovestor, Inc
- | Biotech or pharma, therapeutic R&D
Developing novel antibody drug conjugates (ADCs) from our two innovative ADC platforms, ADoBind and ADoTope, both capable of functionally increasing the antigen copy number on the tumor cells to increase the efficacy and serviceable addressable market for the ADCs. ADoBind platform consists of dimeric IgG1 and ADoTope platform a pair of synergistic antibodies directing at the same antigens. The ADoTope platform allows for dual payload conjugation. These antibodies are also fully human. We have started the IND-enabling studies for our lead ADoBind asset and will start the IND-enabling studies for our lead ADoTope asset in February 2025. Our clinical programs will be in ovarian cancer, pancreatic cancer, and autoimmune diseases.
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}